American Society for Apheresis

View Abstract

CONTROL ID: 4077366

TITLE: TWO PEDIATRIC CASES OF THERAPEUTIC EXCHANGE TO TREAT ELEVATED PLASMA-FREE HEMOGLOBIN

AUTHORS (FIRST NAME INITIAL LAST NAME): N. Tabish[1], K. Annen[2, 1], S. Stephens[2]

INSTITUTIONS (ALL): 1. Pathology/ Blood Banking and Transfusion Medicine, University of Colorado; Childrens Hospital of Colorado, Aurora, CO, United States.
2. Pathology/ Apheresis, Transfusion Medicine and Blood Banking, Childrens Hospital of Colorado, Aurora, CO, United States.

PRESENTATION TYPE: Oral or Poster

CURRENT CATEGORY: Therapeutic Plasma Exchange

ABSTRACT BODY:

Purpose: *When RBCs break down in the bloodstream, hemoglobin (hgb) is released into the plasma. Haptoglobin is the primary protein that binds to hgb, followed by albumin. The reticuloendothelial system rapidly clears hgb from the plasma. In cases of massive intravascular hemolysis, hgb clearance mechanisms may be overwhelmed, accumulating excess plasma free-hgb, which may lead to acute kidney injury and acute tubular necrosis. We present two pediatric cases where Therapeutic Plasma Exchange (TPE) decreased plasma free-hgb.*

Methods :

Case 1: A 19-day-old male infant born at full term with a genetic deletion of 2q24.3-2q32.1, which includes coarctation of the aorta and bicuspid aortic valve. The patient also had Methicillin Susceptible Staphylococcus Aureus (MSSA) bacteremia and E. Coli UTI, which led to multi-organ failure and Disseminated Intravascular Coagulation (ISTH DIC score 5). Over five days, the patient's platelet count dropped precipitously from 182K to 32K, raising concern for thrombocytopenia-associated multi-organ failure (TAMOF). The patient was started on extracorporeal membrane oxygenation (ECMO) without improvement. The clinical team requested TPE for

elevated plasma-free hemoglobin and severe thrombocytopenia. Laboratory tests revealed intravascular hemolysis with elevated tot. Bilirubin (29.8 mg/dL) and LDH (6363 U/L) with ser. Creatinine at 1.02 mg/dL. TPE was performed once daily for three days. The plasma-free hemoglobin (normal range 0-3 mg/dL) was 82.6 (pre-TPE) & 48.3 (post-TPE) at procedure 2 and 49.1 (pre-TPE) & 81.8 (post-TPE) at procedure 3. Upon completion of TPE, the plasma-free hemoglobin elevated to 99.2 and peaked at 1672.5; on this day, the parents opted to withdraw care.

Case 2: A 2-day-old female presented with left ventricular failure of uncertain etiology and was put on venoarterial ECMO. She required fresh frozen plasma (FFP), pRBCs, and platelets due to her initial coagulopathy and bleeding. Blood type was O Rh positive, DAT was negative, and antibody screen was negative. Her blood smear showed a few schistocytes with morphologically normal RBCs. She also developed an intraventricular hemorrhage on head ultrasound. She had significant plasma-free hemoglobin levels and elevated LDH without signs of mechanical hemolysis. As her plasma-free hemoglobin was persistently high, the clinical team requested one 2-volume plasma exchange emergently in tandem with the ECMO circuit. Pre-TPE, the plasma-free hgb was 221 mg/dL; the value was 83.6 on day two after TPE and 0.0 on day three after TPE. Serum creatinine remained within normal limits. The patient made a recovery and is achieving her age-appropriate milestones.

Results : *RESULTS: We demonstrate that TPE reduces plasma-free hemoglobin. Since plasma-free hgb is not dialyzable, TPE may be a viable option for treating elevated plasma-free hgb in critical care.*

Conclusion : *Plasma-free hgb is not categorized in the ASFA guidelines. However, pathophysiology and premise are comparable to Acute Hemolytic Anemia, a Category III indication. Hemoglobinuric acute kidney injury can occur due to several mechanisms, including direct proximal tubular cell toxicity cast formation and other mechanisms and vasoconstriction resulting from plasma free-hgb nitric oxide scavenging. TPE appears effective in reducing plasma-free hemoglobin. However, only one case has previously been reported in the literature. Additional evaluation is needed to determine whether TPE should be recommended as a treatment method.*

DEGREE:
Nabil Tabish : MD
Kyle Annen : Other
Suzan Stephens : RN
DEGREE IF OTHER:
Nabil Tabish : MS

Kyle Annen : DO

PRIMARY AUTHOR?:

Nabil Tabish : Selected

ASFA Membership (Abstract Submission): Yes, I am an ASFA member

ASFA Oral Presentation Awards (ASFA Members and Non-Members): Apply

ASFA Junior Investigator Abstract Award or ASFA Allied Health Abstract Award (ASFA Members Only):

ASFA Junior Investigator Abstract Award

(No Table Selected)

(No Image Selected)
